Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Eligibility criteria:
Inclusion Criteria:

          1. Documentation of Covid-19 infection based on laboratory evidence of positivity by RT-
             PCR.

          2. Patients who have no clinical symptoms (fever, cough and dyspnea).

          3. Patients who have mild clinical symptoms that could include fever, cough, sore throat,
             malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath
             (dyspnea).

          4. Screening laboratory values within institutional normal range or judged to be not
             clinically significant by clinical investigator.

          5. Ability and willingness of subject to give written informed consent.

          6. Negative pregnancy test on the day prior to each vaccination.

          7. Willingness to use adequate contraception by study participants.

        Exclusion Criteria:

          1. History of respiratory and cardiovascular diseases, hematologic disease (e.g.,
             cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus,
             porphyria cutanea tarda).

          2. Autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal,
             hepatic, renal or neurologic disease, which in the opinion of the investigator will
             compromise ability to participate in the study.

          3. Pregnancy and breast-feeding.

          4. Prior or current systemic cancer chemotherapy.

          5. Investigational agents and immunomodulators (cyclosporine, hematological growth
             factors, systemic corticosteroids, interleukins or interferons) within 90 days prior
             to study entry.

          6. Anaphylaxis or allergy to vaccine components.

          7. Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          8. Any other serious diseases other than Covid-19 infection including current or recent
             (within 5 years) cancers.

          9. Subjects who are immunocompromised or immunosuppressed due to disease or medications.

         10. Women who are lactating.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 60 Years

Eligibility (NLI label): Entailment